• QHSLab posted a net loss of USD 103,906 for quarter ended March 31, 2026, as revenue rose 12.9% to USD 728,685 from a year earlier.
• Gross profit increased 9.5% to USD 470,803, while gross margin narrowed 2 percentage points to 64.6% due to changes in revenue mix, including growth in Integrated Service Program (ISP) revenue and a new service line with revenue-sharing arrangements.
• ISP revenue more than doubled to USD 374,501, while allergy diagnostic kit sales fell to USD 228,770 and immunotherapy treatment sales slipped to USD 91,070.
• Sales and marketing expense climbed to USD 218,424, general and administrative costs rose to USD 207,822, while interest expense dropped to USD 9,526 following conversions and settlements of multiple loans in fourth-quarter 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. QHSLab Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-022888), on May 14, 2026, and is solely responsible for the information contained therein.